<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063647</url>
  </required_header>
  <id_info>
    <org_study_id>MC-FludT.6/L</org_study_id>
    <nct_id>NCT01063647</nct_id>
  </id_info>
  <brief_title>Dose-range Finding Treosulfan-based Conditioning</brief_title>
  <official_title>Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Advanced Hematological Malignancies After Treosulfan-based Conditioning Therapy - A Clinical Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety and efficacy of 3 x 10, 3 x 12 or 3 x 14 g/m² Treosulfan resp.,
      combined with 5 x 30 mg/m² fludarabine prior to allogeneic, hematopoietic stem cell
      transplantation of patients with hematological malignancies, but non-eligible to standard
      conditioning treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Evaluation of feasibility and tolerability of 3 x 10, 12 or 14 g/m² Treosulfan combined with 5 x 30 mg/m² fludarabine prior to allogeneic stem cell transplantation • frequency and severity of TRM until 6 months after transplantation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Evaluation of the proportion of relapse- and/or progression free patients six months after transplantation (using standard remission criteria)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>10 g/m² i.v. infusion, day -6, -5, -4</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ovastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>12 g/m² i.v. infusion, day -6, -5, -4</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ovastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>14 g/m² i.v. infusion, day -6, -5, -4</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Ovastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a haematological chemosensitive malignancy indicated for an allogeneic
             transplantation, but presenting an increased toxicity risk for classical (high-dose
             busulfan or standard-dose total body irradiation) conditioning therapies (remission
             criteria ref. to Appendix L):

               -  CML in first or subsequent chronic phase

               -  NHL in 2nd CR/PR, chemosensitive PR after autologous transplantation ; CLL in 2nd
                  or subsequent CR/PR

               -  Relapsed Morbus Hodgkin (MH) after autologous transplantation

               -  Multiple Myeloma (MM) stage II and III according to Durie and Salmon

               -  AML in 2nd CR/PR or high-risk AML in 1st CR/PR

             High-risk defined for example by the following:

               -  Cytogenetics: -5/5q, -7/7q, del(5q), abnormalities of 3q, complex karyotype (&gt; 3
                  abnormalities), or

               -  PR after 1 cycle of induction therapy

               -  ALL in 2nd CR/PR or high-risk ALL in 1st CR/PR

             High-risk defined as follows:

               -  Leukocytes &gt; 3000/µl (B-Linage) or &gt; 100000/µl (T-Linage);

               -  Pro-B-ALL, pre-T-ALL

               -  Cytogenetics: t(9;22)/BCR-ABL; t(4;11)/ALL1-AF

               -  MDS (patients without prior chemotherapy may be included)

          2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor
             (MUD) or one mismatch (out of the 6 standard markers) sibling donor (1 misMRD):

             • HLA-identity defined by the following markers: A, B, DRB1. DQB1 must be recorded.

          3. Age &gt; 18 years

          4. Karnofsky Index &gt; 80 %

          5. Adequate contraception in female patients of child-bearing potential

          6. Co-operative behavior of individual patients

          7. Written informed consent

        Exclusion Criteria:

          1. Completely chemotherapy-resistant disease

          2. Severe cardiac insufficiency, severe cardio-vascular or other severe concomitant
             diseases

          3. Symptomatic malignant involvement of the CNS

          4. Active infectious disease

          5. HIV-positive or active hepatitis infection

          6. Impaired liver function (Bilirubin &gt; 1.5 x upper normal limit; Transaminases &gt; 3.0 x
             upper normal limit)

          7. Impaired renal function (Creatinine-clearance &lt; 60 ml/min; Serum Creatinine &gt; 1.5 x
             upper normal limit).

          8. Pleural effusion or ascites &gt; 1.0 L

          9. Pregnancy or lactation

         10. Known hypersensitivity to fludarabine and/or treosulfan

         11. Parallel participation in another experimental drug trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Freund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5th Medical Clinic, Clinic North</name>
      <address>
        <city>Nuremberg</city>
        <zip>90340</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Medical University</name>
      <address>
        <city>Katowice</city>
        <zip>40-029</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital &amp; Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <last_update_submitted>February 4, 2010</last_update_submitted>
  <last_update_submitted_qc>February 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Joachim Baumgart, PhD</name_title>
    <organization>medac GmbH</organization>
  </responsible_party>
  <keyword>Treosulfan</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>Conditioning therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

